<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–71" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–71/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–71/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_71"><akn:num>379j–71</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>§ 379j–71. Definitions
In this subpart:(1) The term “affiliate” means a business entity that has a relationship with a second business entity if, directly or indirectly—(A) one business entity controls, or has the power to control, the other business entity; or

(B) a third party controls, or has power to control, both of the business entities.


(2) The term “contract manufacturing organization facility” means an OTC monograph drug facility where neither the owner of such manufacturing facility nor any affiliate of such owner or facility sells the OTC monograph drug produced at such facility directly to wholesalers, retailers, or consumers in the United States.

(3) The term “costs of resources allocated for OTC monograph drug activities” means the expenses in connection with OTC monograph drug activities for—(A) officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers, employees, and committees and costs related to contracts with such contractors;

(B) management of information, and the acquisition, maintenance, and repair of computer resources;

(C) leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and

(D) collecting fees under section 379j–72 of this title and accounting for resources allocated for OTC monograph drug activities.


(4) The term “FDA establishment identifier” is the unique number automatically generated by Food and Drug Administration’s Field Accomplishments and Compliance Tracking System (FACTS) (or any successor system).

(5) The term “OTC monograph drug” means a nonprescription drug without an approved new drug application which is governed by the provisions of section 355h of this title.

(6) The term “OTC monograph drug activities” means activities of the Secretary associated with OTC monograph dru</akn:p></akn:content><akn:subsection eId="subsec_379j_71_1"><akn:num>(1)</akn:num><akn:content><akn:p>(1) The term “affiliate” means a business entity that has a relationship with a second business entity if, directly or indirectly—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_2"><akn:num>(2)</akn:num><akn:content><akn:p>(2) The term “contract manufacturing organization facility” means an OTC monograph drug facility where neither the owner of such manufacturing facility nor any affiliate of such owner or facility sells the OTC monograph drug produced at such facility directly to wholesalers, retailers, or consumers in the United States.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_3"><akn:num>(3)</akn:num><akn:content><akn:p>(3) The term “costs of resources allocated for OTC monograph drug activities” means the expenses in connection with OTC monograph drug activities for—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_4"><akn:num>(4)</akn:num><akn:content><akn:p>(4) The term “FDA establishment identifier” is the unique number automatically generated by Food and Drug Administration’s Field Accomplishments and Compliance Tracking System (FACTS) (or any successor system).</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_5"><akn:num>(5)</akn:num><akn:content><akn:p>(5) The term “OTC monograph drug” means a nonprescription drug without an approved new drug application which is governed by the provisions of section 355h of this title.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_6"><akn:num>(6)</akn:num><akn:content><akn:p>(6) The term “OTC monograph drug activities” means activities of the Secretary associated with OTC monograph drugs and inspection of facilities associated with such products, including the following activities:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_7"><akn:num>(7)</akn:num><akn:content><akn:p>(7) The term “OTC monograph order request” means a request for an order submitted under section 355h(b)(5) of this title.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_8"><akn:num>(8)</akn:num><akn:content><akn:p>(8) The term “Tier 1 OTC monograph order request” means any OTC monograph order request not determined to be a Tier 2 OTC monograph order request.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_9"><akn:num>(9)</akn:num><akn:content><akn:p>(9)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_71_10"><akn:num>(10)</akn:num><akn:content><akn:p>(10)</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>